PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT). This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.